Chinese Equity

Total Page:16

File Type:pdf, Size:1020Kb

Chinese Equity Chinese Equity Monthly Update April 2021 Performance (% Total Return) Periods ended April 30, 20211 1 Month YTD Since Inception2 HL Chinese Equity (Gross) 3.39 2.70 2.70 HL Chinese Equity (Net) 3.31 2.37 2.37 MSCI China All Shares Index3,4 2.32 0.79 0.79 Portfolio Positioning (% Weight) Investment Perspectives MSCI Market China All As COVID-19 remains well controlled within China and travel Sector HL CE Shares (Under) / Over restrictions are eased, domestic travel seems poised to rebound Industrials 18.5 7.5 during the longest holiday in the first half of this year, the five-day period beginning on May 1 (known as Labor Day). This augurs well Health Care 14.9 8.9 for leisure- and travel-related businesses. Cons Discretionary 29.9 25.1 Portfolio Cash 1.7 – For US investors in Chinese securities, the Holding Foreign Companies Accountable Act imposed in the waning days of the Trump Info Technology 9.3 8.3 administration is a slow-moving threat—but one from which we have nonetheless chosen to insulate the portfolio altogether. To side-step Comm Services 14.5 14.1 the risk (which we still judge to be low) that ADRs would be de-listed from US exchanges in 2023 either because of non-compliant auditing Utilities 1.5 2.0 standards or purported connections to the Chinese military, we exchanged the four such ADR holdings for the underlying ordinary Energy 0.0 1.3 shares, following their secondary listing in Hong Kong. The strategy no longer holds any US-listed ADRs. Real Estate 0.0 3.4 Cons Staples 5.7 9.2 Materials 0.0 4.5 Financials 4.0 15.7 -12 -6 0 6 12 Top Ten Holdings Company Market Sector Alibaba Mainland China DSCR Tencent Mainland China COMM MSCI China All China Tourism Group Duty Free Mainland China DSCR Geography HL CE Shares (Under) / Over WuXi Biologics Mainland China HLTH Other Emerging Markets5 6.3 – WuXi AppTec Mainland China HLTH AirTAC Taiwan INDU Cash 1.7 – Techtronic Industries Hong Kong INDU Mainland China + Hong Kong 92.0 100.0 Haitian International Mainland China INDU AIA Group Hong Kong FINA -12 -6 0 6 12 Wuliangye Yibin Mainland China STPL Top Ten Holdings are the top ten holdings by weight. Please read the disclosures on the last page, which are an integral part of this presentation. Benchmark Performance | Apr. Benchmark Performance | YTD Total Return by Sector (%) Total Return by Sector (%) 15 15 10 10 5 5 0 0 -5 -5 -10 UTIL UTIL INFT INFT FINA FINA INDU INDU STPL STPL RLST RLST HLTH HLTH ENER DSCR DSCR ENER MATS MATS COMM COMM Portfolio Attribution | Apr. Portfolio Attribution | YTD Effect (%) Selection Allocation Total Effect (%) Selection Allocation Total Sector -0.1 1.2 1.1 Sector 1.4 0.6 2.0 2.0 2.0 1.0 1.0 0.0 0.0 -1.0 -1.0 UTIL UTIL INFT INFT FINA FINA INDU INDU STPL STPL RLST RLST HLTH HLTH ENER DSCR DSCR ENER CASH CASH MATS MATS COMM COMM . The portfolio’s underweight to Financials, especially the absence . Technology outperformed thanks to strong returns in Silergy. of banks, helped relative performance in April. Hong Kong-based . We also outperformed in Industrials where AirTAC, Haitian life insurer AIA Group outperformed, helped by a strong start this International, and Techtronic Industries all reported strong earnings. year with a pandemic recovery bounce in new business in . Our underweights in Materials and Energy sectors hurt relative Mainland China. performance in a period when these sectors have been strong, . Information Technology and Industrials outperformed, helped by buoyed by rising commodity prices. positive stock selection. Silergy, a power-management integrated . In Consumer Staples, our stocks underperformed. Soy sauce maker circuit maker, benefitted from continuation of strong pandemic Foshan Haitian was weak due to the threat of margin pressure from demand for consumer gadgetry. Taiwan-based pneumatic rising commodity prices. component manufacturer AirTAC led in Industrials, with strong Q1 sales and margins, and raised full-year guidance. Consumer Discretionary was a notable drag, where wardrobe and kitchen cabinet maker Suofeiya pulled back in April after a strong run of pandemic stay-at-home DIY and redecorating projects. Top Five Contributors/Detractors (%) | Apr. Top Five Contributors/Detractors (%) | YTD to Relative Returns to Relative Returns Index Index Contributors Market Sector Weight Effect Contributors Market Sector Weight Effect AirTAC Taiwan INDU – 0.63 AirTAC Taiwan INDU – 0.63 Silergy Taiwan INFT – 0.48 Techtronic Industries Hong Kong INDU – 0.58 WuXi AppTec Mainland China HLTH 0.4 0.39 Haitian International Mainland China INDU 0.1 0.55 WuXi Biologics Mainland China HLTH 0.9 0.32 Pinduoduo* Mainland China DSCR 1.3 0.37 ASM Pacific Technology Hong Kong INFT – 0.26 Xiaomi* Mainland China INFT 1.1 0.36 Detractors Detractors SF Holding Mainland China INDU 0.4 -0.55 Tencent Mainland China COMM 9.9 -1.63 Suofeiya Mainland China DSCR <0.1 -0.27 SF Holding Mainland China INDU 0.4 -1.14 TravelSky Technology Mainland China INFT 0.1 -0.22 Alibaba Mainland China DSCR 9.5 -1.01 Shanghai Intl Airport Mainland China INDU 0.1 -0.22 Shanghai Intl Airport Mainland China INDU 0.1 -0.69 Jiangsu Hengrui Medicine Mainland China HLTH 0.5 -0.15 Midea Group Mainland China DSCR 0.1 -0.49 *Company was not held in the portfolio; its absence had an impact on the portfolio’s return relative to the MSCI China All Shares Index. April 2021 Monthly Update Index weight is the average weight of the security in the index over the MTD and YTD periods. 2 Please read the disclosures on the last page, which are an integral part of this presentation. Endnotes (1) The April 2021 Composite performance shown is preliminary (2) Inception date: December 31, 2020 (3) The Benchmark Index (4) Gross of withholding taxes (5) Includes countries listed in emerging markets, excluding Mainland China and Hong Kong. Sources Benchmark Performance: FactSet; MSCI Inc. and S&P. Sector/Geographic Attribution: FactSet; Harding Loevner Chinese Equity Composite; MSCI Inc. and S&P. Sector/Geographic Exposure and Top Ten Holdings: FactSet; Harding Loevner Chinese Equity Model; MSCI Inc. and S&P. Disclosures Composite performance shown is preliminary. For comparison purposes the Composite return is measured against the MSCI China All Shares Total Return Index (Gross). Harding Loevner LP is an investment adviser registered with the Securities and Exchange Commission. Harding Loevner LP is an investment adviser registered with the Securities and Exchange Commission. Harding Loevner claims compliance with the Global Investment Performance Standards (GIPS®). GIPS® is a registered trademark of CFA Institute. CFA Institute does not endorse or promote this organization, nor does it warrant the accuracy or quality of the content contained herein. Harding Loevner has been independently verified for the period November 1, 1989 through December 31, 2020. A firm that claims compliance with the GIPS standards must establish policies and procedures for complying with all the applicable requirements of the GIPS standards. Verification provides assurance on whether the firm's policies and procedures related to composite and pooled fund maintenance, as well as the calculation, presentation, and distribution of performance, have been designed in compliance with the GIPS standards and have been implemented on a firm-wide basis. The verification reports are available upon request. Verification does not ensure the accuracy of any composite presentation. Performance data quoted represents past performance; past performance does not guarantee future results. Returns are presented both gross and net of management fees and include the reinvestment of all income. Net returns are calculated using actual fees. The US dollar is the currency used to express performance. For complete information on the construction and historical record of the Chinese Equity Composite, please contact Harding Loevner at (908) 218-7900 or visit www.hardingloevner.com. The firm maintains a complete list of composite descriptions, a list of limited distribution pooled fund descriptions, and a list of broad distribution pooled funds, which are available upon request. The MSCI China All Shares Index is a free float-adjusted market capitalization index designed to measure large and mid-cap China share classes listed in Hong Kong, Shanghai, Shenzhen, and outside of China. You cannot invest directly in this Index. Companies held in the portfolio during the month appear in bold type; only the first reference to a particular holding appears in bold. The portfolio is actively managed therefore holdings may not be current. They should not be considered recommendations to buy or sell any security. It should not be assumed that investment in the securities identified has been or will be profitable. The portfolio holdings identified above do not represent all of the securities held in the portfolio. To request a complete list of holdings since inception, please contact Harding Loevner. The following information is available upon request: (1) information describing the methodology of the contribution data and (2) a list showing the weight and relative contribution to return of all holdings during the month. Portfolio holdings, portfolio attribution, contributors and detractors, and sector/geographic portfolio positioning are supplemental information only and complement a fully compliant Chinese Equity Composite GIPS Presentation, which is available upon request. The Composite and Attribution returns may show discrepancies due to the different data sources for these returns. Composite performance is obtained from Harding Loevner’s accounting system and Attribution returns are obtained from the FactSet portfolio analysis system. Please note returns from FactSet are not audited for GIPS compliance and are for reference only. FactSet Fundamentals, Copyright 2021 FactSet Research Systems, Inc.
Recommended publications
  • China Multi Asset Income Fund - 3-Year Class USD Fund Volatility
    Principal China Multi Asset Income Fund - 3-year Class USD Fund Volatility 31 August 2021 10.83Low Lipper Analytics 15 Aug 2021 Fund Objective Fund Performance The Fund aims to provide income and 60% moderate capital growth through investments in one CIS, which invests 50% primarily in a diversified portfolio of securities related to China. 40% Currency: ISIN Code: 30% USD MYU1002GD004 20% Bloomberg Ticker: CIMCMUS MK 10% 0% Fund Information 7 7 8 8 8 8 8 8 9 9 9 9 9 9 0 0 0 0 0 0 1 1 1 1 1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 t c b r n g t c b r n l p v n r y l p v n b r n g c e e p u u c e e p u Ju e o a a a Ju e o a e p u u - 10% O D F A J A O D F A J S N J M M S N J F A J A Domicile Malaysia - 20% Base Currency US Dollar (USD) Fund Inception 3 July 2017 Fund Benchmark Benchmark The Fund adheres to the Past performance does not guarantee future results. Asset allocation and diversification do not ensure a profit or protect against a loss. benchmark of the Target Fund for performance Cumulative Performance (%) comparison. The Since YTD 1 Month 3 Months 6 Months 1-Year 3-Year 5-Year Inception benchmark of the Target Fund -8.70 -0.21 -9.33 -10.95 -1.42 17.94 N/A 19.79 Fund is 50% MSCI China Net + 50% Markit Benchmark/Target Return -4.47 0.22 -7.23 -7.95 2.29 22.31 N/A 33.59 iBoxx Asia Local Bond Index China Offshore for Calendar Year Returns (%) 2020 2019 2018 2017 2016 2015 comparison purpose.
    [Show full text]
  • Hang Seng Indexes Announces Index Review Results
    14 August 2020 Hang Seng Indexes Announces Index Review Results Hang Seng Indexes Company Limited (“Hang Seng Indexes”) today announced the results of its review of the Hang Seng Family of Indexes for the quarter ended 30 June 2020. All changes will take effect on 7 September 2020 (Monday). 1. Hang Seng Index The following constituent changes will be made to the Hang Seng Index. The total number of constituents remains unchanged at 50. Inclusion: Code Company 1810 Xiaomi Corporation - W 2269 WuXi Biologics (Cayman) Inc. 9988 Alibaba Group Holding Ltd. - SW Removal: Code Company 83 Sino Land Co. Ltd. 151 Want Want China Holdings Ltd. 1088 China Shenhua Energy Co. Ltd. - H Shares The list of constituents is provided in Appendix 1. The Hang Seng Index Advisory Committee today reviewed the fast expanding innovation and new economy sectors in the Hong Kong capital market and agreed with the proposal from Hang Seng Indexes to conduct a comprehensive study on the composition of the Hang Seng Index. This holistic review will encompass various aspects including, but not limited to, composition and selection of constituents, number of constituents, weightings, and industry and geographical representation, etc. The underlying aim of the study is to ensure the Hang Seng Index continues to serve as the most representative and important benchmark of the Hong Kong stock market. Hang Seng Indexes will report its findings and propose recommendations to the Advisory Committee within six months. The number of constituents of the Hang Seng Index may increase during this period. Hang Seng Indexes Announces Index Review Results /2 2.
    [Show full text]
  • Greater China 2019
    IR Magazine Awards – Greater China 2019 Winners and nominees AWARDS BY RESEARCH Best overall investor relations (large cap) ANTA Sports Products China Resources Beer WINNER China Telecom China Unicom Shenzhou International Group Holdings Best overall investor relations (small to mid-cap) Alibaba Pictures Group Far East Consortium International WINNER Health and Happiness H&H International Holdings Li-Ning NetDragon Websoft Holdings Best investor relations officer (large cap) ANTA Sports Products Suki Wong Cathay Financial Holdings Yajou Chang & Sophia Cheng China Resources Beer Vincent Tse WINNER China Telecom Lisa Lai China Unicom Jacky Yung Best investor relations officer (small to mid-cap) Agile Group Holdings Samson Chan BizLink Holding Tom Huang Far East Consortium International Venus Zhao WINNER Li-Ning Rebecca Zhang Yue Yuen Industrial (Holdings) Olivia Wang Best IR by a senior management team Maggie Wu, CFO & Daniel Zhang, Alibaba Group CEO Tomakin Lai Po-sing, CFO & China Resources Beer Xiaohai Hou, CEO Xiaochu Wang, CEO & Zhu WINNER China Unicom Kebing, CFO Wai Hung Boswell Cheung, CFO & Far East Consortium International David Chiu, Chairman & CEO Ma Jianrong, CEO & Cun Bo Wang, Shenzhou International Group Holdings CFO AWARDS BY REGION Best in region: China Alibaba Pictures Group ANTA Sports Products China Resources Beer WINNER China Telecom China Unicom Shenzhou International Group Holdings Best in region: Hong Kong AIA Group Far East Consortium International WINNER Health and Happiness H&H International Holdings Yue Yuen
    [Show full text]
  • Biologics CDMO Trends and Opportunities in China
    Volume 21 Issue 3 | July/August/September 2020 TM SHOW ISSUE CPhI: Festival of Pharma BIO Investor Forum - Digital 2020 ISPE Annual Meeting & Expo - Virtual CONTRACT MANUFACTURING Biologics CDMO Trends and Opportunities in China SUPPLY CHAIN Building Future-Proof Supply Chains with Graph Technology CLINICAL TRIALS Decentralization: A Direct Approach to Clinical Trials www.pharmoutsourcing.com Large enough to deliver, small enough to care. Balancing... ANALYTICAL SERVICES With over seven decades of experience, Mission Pharmacal Liquids has mastered the equilibrium of expertise and efficiency. DEVELOPMENT Our mid-sized advantage allows flexibility, responsiveness, and unmatched support in executing your vision while MANUFACTURING Semi-Solids providing a wide range of specialized services for products at any stage of their life cycle. Regardless of REGULATORY SUPPORT Tablets the scope and size of your project, we will create a custom program to meet your individual requirements and PACKAGING exceed expectations. Delivering on our ability to produce small or large scale, while providing personalized service and attention to detail on any sized project. missionpharmacal.com Contact us: [email protected] Copyright © 2020 Mission Pharmacal Company. All rights reserved. CDM-P2011912 A HEALTHY WORLD WITH AJINOMOTO BIO-PHARMA SERVICES, YOU HAVE THE POWER TO MAKE. To make your vision a reality. To make your program a sucess. To make a positive difference in the world. Your programs deserve the most comprehensive suite of CDMO services available, and Ajinomoto Bio-Pharma Services has the Power to Make your therapeutic vision a reality - from preclinical through commerical production. CDMO SERVICES: Small Molecules Large Molecules Process Development Oligos & Peptides High Potency & ADC Aseptic Fill Finish WHAT DO YOU WANT TO MAKE? www.AjiBio-Pharma.com FROM THE EDITOR Editor's Message Effi ciency: One Step at a Time I like to think that in a previous life (or maybe in a future life) I was an effi ciency expert.
    [Show full text]
  • HSBC Emerging Market Sustainable Equity UCITS ETF
    Sustainably Invested MX-PE HSBC ETFs PLC - HSBC Emerging Market Sustainable Equity UCITS ETF HSEF LN Aug 31 2021 Fund IE00BKY59G90 Aug 31 2021 Fund Objective and Strategy Investment Objective The Fund aims to track as closely as possible the returns of the FTSE Emerging ESG Low Carbon Select Index (the “Index”). The Fund will invest in or gain exposure to shares of companies which make up the Index. Investment Policy The Index seeks to achieve a reduction in carbon emissions and fossil fuel reserves exposure, improvement of the FTSE Russell ESG rating and also applies the United Nations Global Compact exclusionary criteria.The Fund will be passively managed and will aim to invest in the shares of the companies in generally the same proportion as in the Index. However, there may be circumstances when it is not possible or practical for the Fund to invest in all constituents of the Index. The Fund can gain exposure by using other investments such as depositary receipts, derivatives or funds.The Fund may invest up to 35% in securities from a single issuer during exceptional market conditions.The Fund may invest up to 10% in funds and up to 10% in total return swaps and contracts for difference.See the Prospectus for a full description of the investment objectives and derivative usage. Since Inception Performance (%) Fund Details UCITS V Compliant Yes 130 Fund Reference Benchmark 125 Distribution Type Accumulating 120 2 115 Ongoing Charge Figure 0.180% 110 105 Share Class Base Currency USD 100 95 90 Domicile Ireland ISIN IE00BKY59G90 Share
    [Show full text]
  • HSBC Global Investment Funds CHINESE EQUITY Monthly Report 31 August 2021 | Share Class IC
    HSBC Global Investment Funds CHINESE EQUITY Monthly report 31 August 2021 | Share class IC Share Class Details Investment objective Key metrics The Fund aims to provide long term capital growth by investing in a portfolio of Chinese shares. NAV per Share USD 163.81 Performance 1 month -0.91% Investment strategy Volatility 3 years 21.14% Fund facts In normal market conditions, the Fund will invest at least 90% of its assets in shares (or securities UCITS V compliant Yes similar to shares) of companies of any size that are based in, or carry out the larger part of their business activities in, China, including Hong Kong SAR. The Fund can invest up to 70% in China Dividend treatment Accumulating A and China B-shares. For China A-shares, up to 70% through the Shanghai-Hong Kong Stock Dealing frequency Daily Connect and/or the Shenzhen-Hong Kong Stock Connect, and up to 50% in CAAPs. The Fund Valuation Time 17:00 Luxembourg may invest up to 10% of its assets in other funds, including HSBC funds. The Fund will not invest more than 10% of its assets in Real Estate Investment Trusts. See the Prospectus for a full Share Class Base Currency USD description of the investment objectives and derivative usage. Domicile Luxembourg Inception date 27 July 2005 Main risks Fund Size USD 1,139,298,382 Reference 100% MSCI China 10/40 • The Fund's unit value can go up as well as down, and any capital invested in the Fund may benchmark Net be at risk. • The value of investible securities can change over time due to a wide variety of factors, Managers Caroline Yu Maurer including but not limited to: political and economic news, government policy, changes in Fees and expenses demographics, cultures and populations, natural or human-caused disasters etc.
    [Show full text]
  • MSCI China Index (USD)
    MSCI China Index (USD) The MSCI China Index captures large and mid cap representation across China A shares, H shares, B shares, Red chips, P chips and foreign listings (e.g. ADRs). With 730 constituents, the index covers about 85% of this China equity universe. Currently, the index includes Large Cap A and Mid Cap A shares represented at 20% of their free float adjusted market capitalization. CUMULATIVE INDEX PERFORMANCE — GROSS RETURNS (USD) ANNUAL PERFORMANCE (%) (AUG 2006 – AUG 2021) MSCI Year MSCI China Emerging MSCI ACWI Markets MSCI China 2020 29.67 18.69 16.82 MSCI Emerging Markets 2019 23.66 18.88 27.30 MSCI ACWI 2018 -18.75 -14.24 -8.93 400 2017 54.33 37.75 24.62 366.92 2016 1.11 11.60 8.48 324.55 2015 -7.62 -14.60 -1.84 2014 8.26 -1.82 4.71 2013 3.96 -2.27 23.44 252.73 2012 23.10 18.63 16.80 200 2011 -18.24 -18.17 -6.86 2010 4.83 19.20 13.21 2009 62.63 79.02 35.41 2008 -50.83 -53.18 -41.85 50 2007 66.24 39.82 12.18 Aug 06 Nov 07 Feb 09 May 10 Aug 11 Nov 12 Feb 14 May 15 Aug 16 Nov 17 Feb 19 May 20 Aug 21 INDEX PERFORMANCE — GROSS RETURNS (%) (AUG 31, 2021) FUNDAMENTALS (AUG 31, 2021) ANNUALIZED Since 1 Mo 3 Mo 1 Yr YTD 3 Yr 5 Yr 10 Yr Dec 31, 1992 Div Yld (%) P/E P/E Fwd P/BV MSCI China 0.01 -13.69 -5.00 -12.18 7.42 10.97 7.47 2.18 1.61 15.47 13.57 1.91 MSCI Emerging Markets 2.65 -4.00 21.49 3.07 10.25 10.80 5.22 7.75 2.07 15.98 13.07 2.00 MSCI ACWI 2.53 4.67 29.18 16.24 14.91 14.88 11.86 8.88 1.71 22.54 18.46 3.07 INDEX RISK AND RETURN CHARACTERISTICS (AUG 31, 2021) ANNUALIZED STD DEV (%) 2 SHARPE RATIO 2 , 3 MAXIMUM DRAWDOWN Turnover Since 1 3 Yr 5 Yr 10 Yr 3 Yr 5 Yr 10 Yr Dec 31, (%) Period YYYY-MM-DD (%) 1992 MSCI China 8.79 21.43 19.19 20.89 0.38 0.57 0.42 0.14 88.63 1993-12-31—2001-09-12 MSCI Emerging Markets 8.45 19.23 16.52 17.57 0.54 0.63 0.34 0.33 65.14 2007-10-29—2008-10-27 MSCI ACWI 3.17 17.93 14.46 13.77 0.80 0.95 0.83 0.47 58.06 2007-10-31—2009-03-09 1 Last 12 months 2 Based on monthly gross returns data 3 Based on ICE LIBOR 1M The China mainland equity market is comprised of A, B, H, Red chip and P chip share classes.
    [Show full text]
  • Ireland Asia Report Ireland Asia Report Table of Contents
    Ireland Asia Report Ireland Asia Report Table of Contents Ireland as an FDI location for Asian companies Martin Shanahan, CEO, IDA Ireland 2 Ireland’s open economy and its role in the Future of Global Trade Alan Duffy, CEO & Head of Banking, HSBC Ireland 4 An ideal gateway to Europe William Wu, Managing Director, Head of Corporate Banking Yangtze Delta and Western China at HSBC China 7 Asia Market Profiles 8 Mainland China and WuXi Biologics 8 Hong Kong and Goshawk 10 Japan and Indeed.com 12 India and NIIT 14 South Korea and SK Biotek 16 ASEAN and Keppel 18 The Ireland advantage for funds 20 Ireland – a well-rounded destination for people and investment, Chen Tian, Head of China Desk, Continental Europe, Commercial Banking, HSBC 22 Page 1 Ireland Asia Report Ireland Asia Report Ireland as an FDI location for Asian Companies Yet although there may be some unpredictable times Martin Shanahan, ahead, I remain confident in Ireland’s competitiveness CEO IDA Ireland and attractiveness as a place to do business. From regular recent contact between IDA Ireland and many of the leading multinationals here, I know how resilient these companies’ Irish operations are. I believe the supports that Ireland, as a nation, puts in place to welcome international investment are a key factor in this durability. The disruption to supply chains brought about by the We are all still coming to terms with crisis has highlighted how important it is to manage risk and avoid overdependency on a single source. If the shock that the Covid-19 crisis we apply this to an Irish context, it means not relying has delivered to our economy and on any one geographical region or industry sector for society.
    [Show full text]
  • China's Healthcare System Uncovered
    China’s Healthcare System Uncovered Theme Focus: Online Medicine and Potential Beneficiaries of the COVID-19 Virus Pandemic Q1 2020 KURE Quarterly Earnings Report [email protected] +1 (212) 933 0393 [email protected] +1 (212) 933 0393 Table of Contents KURE Standard Performance 3 China's Healthcare System Uncovered 4 Key Points on China Healthcare Sector 5 China Healthcare Sector Key Charts 6-7 Q1 2020 Performance Review 8 Online Medicine and Beneficiaries of the COVID-19 9-12 Virus Pandemic Overview 12-17 Top 10 KURE Holdings: Quarterly Earnings Update 18-26 Jiangsu Hengrui Med 18 Shenzhen Mindray 19 Wuxi Biologics 20-21 CSPC Pharmaceutical Group 21-22 Sino Biopharmaceutical 22-23 WuXi AppTec 23 Aier Eye Hospital Group 24 Yunnan Baiyao Group 25 Changchun High & New Tech 25 Innovent Biologics 26 Potential Risks 27-29 Citations 30 Definitions 30 kraneshares.com 2 [email protected] +1 (212) 933 0393 KraneShares MSCI All China Health Care Index ETF (Ticker: KURE) Standard Performance Cumulative % Data as of: 03/31/2020 Fund NAV Closing Price Index 1 Month -3.84% -5.34% -3.85% 3 Month 2.10% 3.03% 2.20% 6 Month 12.82% 13.26% 13.20% Since Inception -4.22% -4.26% -3.51% Avg Annualized % Data as of: 03/31/2020 Fund NAV Closing Price Index 1 Year 6.95% 7.58% 7.80% Since Inception -1.97% -1.99% -1.64% KURE’s gross expense ratio is 0.79%. Inception Date: 1/31/2018. The performance data quoted represents past performance. Past performance does not guarantee future results.
    [Show full text]
  • Non-Collateralised Structured Products CREDIT SUISSE AG
    Announcement on Valuation of Residual Value Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the stock exchange) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Non-Collateralised Structured Products Notice of Valuation of Residual Value of European Style (Cash Settled) Category R Callable Bull/Bear Contracts (the CBBCs) issued by CREDIT SUISSE AG (incorporated with limited liability under the laws of Switzerland) Sponsor/Manager CREDIT SUISSE (HONG KONG) LIMITED Terms not defined in this announcement have the same meaning as defined in the general conditions and the product conditions of the CBBCs (together, the conditions). Credit Suisse AG (the issuer) announces that under the conditions, following the occurrence of a mandatory call event (MCE) in respect of the CBBCs described in the table below in the pre- opening session or the continuous trading session or the closing auction session (as the case may be) of the stock exchange at the time (MCE time) and on the date (MCE date) specified in the table below, the amount of the residual value in respect of the CBBCs has been determined as follows: Stock Type MCE MCE Underlying Issue Size Number of Entitlement Board Lot Strike Maximum/ Residual Value Code Time Date (CBBCs) CBBC(s) (CBBCs) Price Minimum Trade per Board Lot per (HK$) Price (HK$) (HK$) Entitlement 52208 Bull 11:02:46 6 Jul 2021 WuXi Biologics (Cayman) Inc.
    [Show full text]
  • HSBC Global Investment Funds - Hong Kong Equity
    BM-BE HSBC Global Investment Funds - Hong Kong Equity Share Class PD 31 Jul 2021 PD LU0011817854 31/07/2021 Fund Objective and Strategy Investment Objective The Fund aims to provide long term capital growth by investing in a portfolio of Hong Kong SAR shares. Investment Policy In normal market conditions, the Fund will invest at least 90% of its assets in shares (or securities similar to shares) of companies of any size that are based in, or carry out the larger part of their business activities in, Hong Kong SAR.The Fund can invest up to 20% in China A and China B-shares. For China A-shares, up to 20% through the Shanghai-Hong Kong Stock Connect and/or the Shenzhen-Hong Kong Stock Connect, and up to 10% in CAAPs.The Fund may invest up to 10% in other funds, including HSBC funds.The Fund will not invest more than 10% in Real Estate Investment Trusts.See the Prospectus for a full description of the investment objectives and derivative usage. Share Class Details UCITS V Compliant Yes Performance (%) YTD 1M 3M 1Y 3Y¹ 5Y¹ Distribution Type Distributing PD -8.41 -9.67 -8.07 6.15 4.75 8.41 Distribution Frequency Annually Reference Dividend ex-date 08 Jul 2021 -5.59 -10.58 -10.06 9.13 3.25 9.08 Benchmark Dividend Yield 2 0.26% Last Paid Dividend 0.3857 Rolling Dealing Frequency Daily 31 Jul 2020-31 31 Jul 2019- 31 Jul 2018- 31 Jul 2017- 31 Jul 2016- Performance Valuation Time 17:00 Luxembourg Jul 2021 31 Jul 2020 31 Jul 2019 31 Jul 2018 31 Jul 2017 (%) Min.
    [Show full text]
  • Altimeo Asset Management, Et Al. V. Wuxi Pharmatech (Cayman) Inc., Et Al. 19-CV-01654-Consolidated Amended Class Action Complain
    Case 1:19-cv-01654-AJN Document 39 Filed 08/05/19 Page 1 of 114 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ALTIMEO ASSET MANAGEMENT, Case No. 1:19-cv-01654-AJN Individually and On Behalf of All Others Similarly Situated, CLASS ACTION Plaintiff, CONSOLIDATED AMENDED CLASS ACTION COMPLAINT v. JURY TRIAL DEMANDED WUXI PHARMATECH (CAYMAN) INC., GE LI, EDWARD HU, NING ZHAO, XIAOZHONG LIU, ZHAOHUI ZHANG, G&C PARTNERSHIP L.P., ABG II-WX LIMITED, BOYU CAPITAL FUND II, L.P., HILLHOUSE CAPITAL FUND II, L.P., PING AN LIFE INSURANCE COMPANY OF CHINA. LTD., TEMASEK LIFE SCIENCES PRIVATE LIMITED, G&C IV LIMITED, YINFU CAPITAL MANAGEMENT CO., YUNFENG II WX LIMITED, SEQUOIA CAPITAL CHINA GROWTH FUND III, L.P., CONSTANT CYPRESS LIMITED, and SPDB INTERNATIONAL HOLDINGS LIMITED, Defendants. Case 1:19-cv-01654-AJN Document 39 Filed 08/05/19 Page 2 of 114 TABLE OF CONTENTS I. NATURE OF THE ACTION ............................................................................................. 1 II. JURISDICTION AND VENUE ......................................................................................... 6 III. PARTIES ............................................................................................................................ 7 A. Lead Plaintiff .......................................................................................................... 7 B. Defendants .............................................................................................................. 7 1. The Individual Defendants .........................................................................
    [Show full text]